Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

about

Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Item

http://www.wikidata.org/entity/Q47680007

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@en

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@nl

type

Item

label

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@en

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@nl

prefLabel

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@en

Sacubitril/valsartan instead o ...... ard in resistant hypertension.

@nl

P1476

Sacubitril/valsartan instead o ...... ward in resistant hypertension

@en

P2093

Michael Doumas

http://www.w3.org/2001/XMLSchema#string

P2860

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

Diurnal blood pressure variation, risk categories and antihypertensive treatment.

Resistant hypertension--its identification and epidemiology.

Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

P304

65-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCH.13146

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Konstantinos Stavropoulos

Konstantinos P Imprialos

P577

2017-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29237097

http://www.w3.org/2001/XMLSchema#string